GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (LSE:CTEC) » Definitions » Cash Flow from Financing

ConvaTec Group (LSE:CTEC) Cash Flow from Financing : £-98 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is ConvaTec Group Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, ConvaTec Group paid £0 Mil more to buy back shares than it received from issuing new shares. It spent £118 Mil paying down its debt. It paid £0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent £18 Mil paying cash dividends to shareholders. It received £0 Mil on other financial activities. In all, ConvaTec Group spent £136 Mil on financial activities for the six months ended in Dec. 2023.


ConvaTec Group Cash Flow from Financing Historical Data

The historical data trend for ConvaTec Group's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ConvaTec Group Cash Flow from Financing Chart

ConvaTec Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -192.66 -120.60 -150.33 -194.66 -97.96

ConvaTec Group Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.82 -43.69 -150.49 47.36 -145.20

ConvaTec Group Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

ConvaTec Group's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

ConvaTec Group's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ConvaTec Group  (LSE:CTEC) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

ConvaTec Group's issuance of stock for the six months ended in Dec. 2023 was £0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

ConvaTec Group's repurchase of stock for the six months ended in Dec. 2023 was £0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

ConvaTec Group's net issuance of debt for the six months ended in Dec. 2023 was £-118 Mil. ConvaTec Group spent £118 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

ConvaTec Group's net issuance of preferred for the six months ended in Dec. 2023 was £0 Mil. ConvaTec Group paid £0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

ConvaTec Group's cash flow for dividends for the six months ended in Dec. 2023 was £-18 Mil. ConvaTec Group spent £18 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

ConvaTec Group's other financing for the six months ended in Dec. 2023 was £0 Mil. ConvaTec Group received £0 Mil on other financial activities.


ConvaTec Group Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


ConvaTec Group (LSE:CTEC) Business Description

Traded in Other Exchanges
Address
23 Forbury Road, 3 Forbury Place, Reading, GBR, RG1 3JH
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and continence care are the largest divisions, accounting for 30% and 26% of total revenue, respectively. Ostomy contributes 25% of revenue and infusion sets 19%.

ConvaTec Group (LSE:CTEC) Headlines